Ponezumab (APP Abeta40) - Research Grade Biosimilar
Product Specifications
Background
Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease) .
Immunogen
Humanized / APP Abeta40 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Neuroscience
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Fragment
IgG2-kappa
NCBI Organism
Homo sapiens
Other Product Names
PF-04360365, RN-1219, clone 9TL
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940270-100 1x 100 µL
Fibronectin (HFN7.1), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471037-100 1x 100 µL
CD44 Standard (DF1485), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC610470-100 1x 100 µL
CD45 / LCA (2B11), CF660R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680334-100 1x 100 µL
Cytokeratin 8 (H1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details